Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study

Abstract

Erenumab was effective in migraine patients who were highly refractory to previous prophylactics. As a practical guideline, we propose that treatment be continued for at least 6 months and that patients with a ≥30% MMD reduction in at least half of the treatment period should be considered to be responders.